Edwards Lifesciences

US · EW #442 by market cap Listed 1970

85.78 -0.70 -0.81%

Live - 5344 symbols - heartbeat 80s ago · 2026-10-08 04:00

Pre-market 85.78 0.00%

After-hours 85.78 0.00%

Market cap: 49.44B
P/E (TTM): 49.87
P/B: 4.66
EPS: 1.83
Div yield: 0.00%
52W pos: 56%

Reader sentiment Are you bullish or bearish on EW?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Distributing

The number of reporting institutions decreased by 7 in the most recent period (2026/Q3).
Total institutional ownership fell 0.3 percentage points.

Institutional ownership

Held by institutions: 93.23% -0.26pp
Institutions: 1,629 -7
As of: 2026/Q3 vs. prior period

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Mutual Fund78.28%

Hedge Fund4.24%

Public Company3.56%

Government Pension Fund2.17%

Sovereign Wealth Fund1.54%

Private Company1.40%

VC/PE Fund1.17%

Insurance Company0.32%

Individual/Insider0.22%

Other7.10%

Top holders as of 2026-06-30

BlackRock 10.20% · 58.79M sh

Vanguard Capital Management, LLC 7.09% · 40.85M sh

Vanguard Portfolio Management, LLC 4.58% · 26.41M sh

State Street Global Advisors 4.57% · 26.32M sh

J.P. Morgan Asset Management, Inc. 3.38% · 19.49M sh

Wellington Management Group 2.92% · 16.83M sh

Geode Capital Management, LLC 2.68% · 15.44M sh

Ninety One UK Limited 2.29% · 13.22M sh

Union Asset Management Holding AG 2.26% · 13.00M sh

Aristotle Capital Management, LLC 1.50% · 8.67M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 16 buys · 34 sells

Name	Role	Stake
Scott Ullem	Corporate VP & CFO	0.05%
Larry Wood	Corporate VP and Group President of TAVR & Surgical Structural Heart	0.03%
Jean-Luc Lemercier	Corporate Vice President of Japan, Asia Pacific & Greater China	0.03%
Donald Bobo	Corporate Vice President of Strategy & Corporate Development	0.02%
Bernard Zovighian	Chief Executive Officer	0.02%
Steven Loranger	Independent Director	0.01%
Kieran Gallahue	Independent Director	0.01%
Nicholas Valeriani	Independent Director	0.01%
Leslie Heisz	Independent Director	0.01%
Daveen Chopra	Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies	0.00%

Insider transactions most recent Form 4 filings

Date	Name	Role	Type	Shares	Price
2026-09-13	Wayne Markowitz	GM & Senior VP of Surgical	Sale to Issuer	-923	$84.37–86.77
2026-09-12	Andrew Dahl	Officer	Sale to Issuer	-253	$84.37
2026-09-10	Daveen Chopra	Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies	Sale to Issuer	-398	$86.77
2026-09-10	Daniel Lippis	CVP of JAPAC	Derivative Exercise and Sale	-619	$72.68–87.51
2026-08-30	Andrew Dahl	Officer	Open Market Disposition	-544	$91.06
2026-08-27	Annette Bruls	Corporate Vice President of EMEA, Canada, & Latin America	Open Market Disposition	-2,644	$89.98
2026-08-25	Daveen Chopra	Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies	Derivative Exercise and Sale	-31,800	$72.68–91.76
2026-08-25	Wayne Markowitz	GM & Senior VP of Surgical	Open Market Disposition	-1,240	$91.47
2026-08-10	Daniel Lippis	CVP of JAPAC	Derivative Exercise and Sale	-619	$72.68–92.03
2026-07-29	Scott Ullem	Corporate VP & CFO	Intent to Sell (Form 144)	-50,000	$92.50
2026-07-29	Wayne Markowitz	GM & Senior VP of Surgical	Open Market Disposition	-146	$86.03
2026-07-27	Wayne Markowitz	GM & Senior VP of Surgical	Derivative Exercise and Sale	-9,628	$74.02–85.06
2026-07-26	Bernard Zovighian	Chief Executive Officer	Other Acquisition	+319	--
2026-07-26	Bernard Zovighian	Chief Executive Officer	Other Disposition	-319	--
2026-07-26	Bernard Zovighian	Chief Executive Officer	Open Market Disposition	-2,920	$83.93
2026-07-10	Annette Bruls	Corporate Vice President of EMEA, Canada, & Latin America	Sale to Issuer	-109	$92.21
2026-07-09	Daniel Lippis	CVP of JAPAC	Derivative Exercise and Sale	-619	$72.68–91.70
2026-07-08	Theodora Mistras	Corporate VP & CFO	Other Acquisition	+99,920	--
2026-07-08	Theodora Mistras	Corporate VP & CFO	Other Derivative Acquisition	+12,325	--
2026-07-08	Theodora Mistras	Corporate VP & CFO	Other Derivative Acquisition	+61,800	$91.33

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 04:00:07 · For reference only, not investment advice and not tailored to your situation.